Farhat’s translational research portfolio, encompassing both basic laboratory research and clinical studies, centers around understanding and modifying risk factors for colorectal cancer. She was awarded a Cancer Research UK Clinician Scientist Fellowship in 2010 and currently holds a Chief Scientist Office Senior Clinical Fellowship.

Colorectal cancer is a major cause of cancer death worldwide; understanding the cellular signaling that governs growth of cancer cells holds the key to developing novel drugs that interfere with cancer cell proliferation. Research in Farhat’s lab focuses on colorectal cancer prevention by investigating energy and metabolism signaling pathways that are associated with risk factors such as obesity and physical inactivity and are dysregulated in colorectal cancer. In parallel, research focuses on how known chemopreventive agents such as aspirin and metformin may realign such aberrant signaling and cancer stem cells in colorectal cancer. The group are working to identify specific biomarkers in patients with particular risk factors, for example, diabetes or obesity, in order to tailor precision prevention strategies based on an individual’s risk factors.

In addition to her translational laboratory research, Farhat is actively involved in clinical trials, being the local principle investigator on several national trials. She has contributed nationally to the NICE guidance on the use of faecal immunochemical testing in low risk populations and is undertaking a funded project to establish its safe use in high-risk symptomatic patients.

Alongside her clinical practice and research activities, Farhat has a keen interest in surgical career development, being an enthusiastic surgical mentor. She contributes to several scientific committees including CRUK’s Research Careers Committee.